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1  | INTRODUC TION
Spinal cord injury can lead to extensive damage to the nervous tissue 
resulting in serious deficits in sensorimotor functions. Neuronal cell 
death and glial cell death occur either rapidly following the initial 
mechanical damage, or during the following secondary phase that 
can last for weeks and which involves a neuroinflammatory response 
to the injury.1
Resident astrocytes and microglia, as well as immune cells in‐
filtrating the spinal cord after the injury, mediate the neuroinflam‐
matory response and secrete several pro‐inflammatory cytokines, 
including tumor necrosis factor (TNF).
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Summary
Aim: The activation of the TNFR2 receptor is beneficial in several pathologies of the 
central nervous system, and this study examines whether it can ameliorate the recov‐
ery process following spinal cord injury.
Methods: EHD2‐sc‐mTNFR2, an agonist specific for TNFR2, was used to treat neu‐
rons exposed to high levels of glutamate in vitro. In vivo, it was infused directly to the 
spinal cord via osmotic pumps immediately after a contusion to the cord at the T9 
level. Locomotion behavior was assessed for 6 weeks, and the tissue was analyzed 
(lesion size, RNA and protein expression, cell death) after injury. Somatosensory 
evoked potentials were also measured in response to hindlimb stimulation.
Results: The activation of TNFR2 protected neurons from glutamate‐mediated exci‐
totoxicity through the activation of phosphoinositide‐3 kinase gamma in vitro and 
improved the locomotion of animals following spinal cord injury. The extent of the 
injury was not affected by infusing EHD2‐sc‐mTNFR2, but higher levels of neurofila‐
ment H and 2′, 3′-cyclic-nucleotide 3′-phosphodiesterase were observed 6 weeks 
after the injury. Finally, the activation of TNFR2 after injury increased the neural re‐
sponse recorded in the cortex following hindlimb stimulation.
Conclusion: The activation of TNFR2 in the spinal cord following contusive injury 
leads to enhanced locomotion and better cortical responses to hindlimb stimulation.
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Tumor necrosis factor is essential in triggering healing mecha‐
nisms but can initiate both cell death or survival pathways depend‐
ing on the pathophysiological conditions. It is produced under two 
biologically active forms, a soluble one (solTNF) resulting from the 
regulated cleavage of the extracellular domain of the transmem‐
brane form (tmTNF). SolTNF signals specifically through the ubiq‐
uitously expressed receptor TNFR1, while tmTNF is able to bind 
both TNFR1 and TNFR2.2 Unlike TNFR1, TNFR2 is expressed by a 
restricted number of cells (immune cells, endothelial cells, as well 
as neurons, astrocytes, and oligodendrocytes in the central nervous 
system (CNS)) and lacks a death domain, therefore triggering mostly 
prosurvival pathways by activating phosphoinositide‐3 kinase (PI3K) 
and NF‐κB.3,4
Although the inhibition of TNF (both soluble and transmem‐
brane forms) in clinical trials, aimed at treating patients suffering 
from multiple sclerosis, surprisingly exacerbated the disease,5,6 
there are many examples of favorable outcomes when only the 
signals elicited by solTNF are inhibited while TNFR2 signaling is 
maintained, demonstrating the beneficial effects of tmTNF in CNS 
pathologies. Studies in experimental autoimmune encephalomyeli‐
tis (EAE), a murine model of MS, describe a more severe pathology 
in animals lacking TNFR2 expression.7 Moreover, selective inhibi‐
tion of solTNF results in an improved clinical outcome, whereas 
inhibitors blocking all TNF signaling did not have any noticeable 
effect on the disease course.8 TNFR2 activity also promotes remy‐
elination and oligodendrocyte precursor cells (OPCs) proliferation 
after cuprizone-induced demyelination,9 the proliferation of OPCs 
being mediated by CXCL12 released from activated astrocytes 
through TNFR2 signaling.10 TNFR2 can also protect OPCs from ox‐
idative stress.11
In vitro studies have shed some light on the protective effects 
and mechanisms mediated by TNFR2: Inhibition of TNFR2 in neuro‐
nal cells enhanced the susceptibility of these cells to hypoxic insults 
or beta‐amyloid toxicity,12 whereas oligodendrocytes matured in re‐
sponse to leukemia inhibitory factor (LIF) secreted by astrocytes in 
response to TNFR2 stimulation.13
In the case of spinal cord injury, solTNF is upregulated and con‐
tributes to apoptosis,14 an increased trafficking of AMPA recep‐
tors at the plasma membrane triggered by TNF exacerbating the 
process.15 The lack of either both TNF forms16 or solTNF only17 
does not provide any protection or improvement following injury; 
however, short‐term inhibition of solTNF (3 days) signaling is ben‐
eficial.18 After having reported a decreased expression of TNFR2 
in the latter study after spinal cord injury and having observed 
effects of TNFR2 signaling in neurons and OPCs in vitro that one 
might consider beneficial after a traumatic insult to the cord, we 
wondered whether enhancing TNFR2 signaling activity through 
stimulation with a specific agonist might enhance recovery. Our 
data show that in vitro TNFR2 stimulation protects neurons against 
glutamate‐induced cytotoxicity. In vivo, following spinal cord injury, 
stimulation of TNFR2 helps improving locomotion, as well as re‐
modeling neuronal circuitry.
2  | MATERIAL S AND METHODS
2.1 | Cell culture
The EHD2‐sc‐mTNFR2 agonist was described previously.
19 E18 rat 
cortical neurons purchased from Neurons-R-Us (Mahoney Institute 
of Neurological Sciences, University of Pennsylvania) were cultured 
in Neurobasal medium (Thermo Fisher) supplemented with B27 
on poly-D-lysine/laminin-coated 96-well plates (105 cells/well) for 
7 days before treatments.
2.2 | Cell death assay
Neurons were pretreated with the TNFR2‐specific agonist EHD2‐sc‐
mTNFR2 (1 µg/mL) before stimulation with glutamate (300 µmol/L) 
for one hour. A66 (0.2 µmol/L), AS 605240 (32 nmol/L), and 
SB203580 (5 µmol/L) (Tocris) (respectively, inhibitors of the PI3K 
catalytic subunits p110α and p110γ, and p38 MAPK) were added at 
the same time as the EHD2‐sc‐TNFR2 agonist.
Cell death was assessed by staining with the HCS LIVE/DEAD 
Green Kit (Thermo Fisher). Briefly, the neurons were incubated with 
the Image-iT DEAD Green solution for 30 minutes. The cells were 
then washed with phosphate‐buffered saline (PBS) three times and 
fixed using 16% paraformaldehyde (PFA) for 15 minutes, and all nu‐
clei were counterstained with Hoechst 33342. PBS was then added 
to each well before imaging on a Zeiss Axio Observer wide field mi‐
croscope using a 5× objective.
2.3 | Mice and spinal cord injury
All animal experiments followed NIH and Drexel University IACUC 
guidelines for the use of laboratory animals.
Adult female C57Bl/6 mice (3 months old) were purchased 
from Jackson Laboratory and were acclimated for at least 1 week 
before undergoing surgery as previously described.18 Briefly, fol‐
lowing anesthesia with ketamine (100 mg/kg) and xylazine (10 mg/
kg), a laminectomy was performed at thoracic level T9 and the ex‐
posed spinal cord was contused using the Infinite Horizon impactor 
(Precision Systems and Instrumentation, LLC) with a desired force 
of 65 kDynes. Following injury, muscles of the back, as well as the 
skin, were sutured. After injury, lactated Ringer's solution was ad‐
ministered subcutaneously twice daily for at least 7 days to prevent 
dehydration, buprenorphine (0.1 mg/kg) twice a day for 2 days for 
pain relief and gentamicin (80 mg/kg) once a day for 7 days as a pre‐
ventive measure against bladder infection. Bladders were expressed 
twice daily until normal function was recovered. Data related to the 
injuries are reported in Table S1.
2.4 | Drug administration
Micro-osmotic pumps connected to brain infusion kits III (ALZET), 
affixed to the vertebrae with the cannula placed above the lesion 
immediately following injury, were used to deliver EHD2‐sc‐mTNFR2. 
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The concentrations were adjusted according to the experiment con‐
ducted to maintain daily delivery of similar amounts: 10 mg/mL for 
28 days of delivery (model 1004:0.11 µL/h; BMS, 6 weeks of protein 
analysis), 4.4 mg/mL for 14 days of delivery (model 1002:0.25 µL/h; 
2 weeks of protein analysis, electrophysiology), and 1.1 mg/mL for 
3 days of delivery (model 1003D: 1 µL/h; RNA analysis).
2.5 | Electrophysiology and locomotion behavior
The animals' locomotion during the recovery period was assessed 
using the BMS scoring system developed by Basso et al.20 The ani‐
mals were tested at day 1 after injury (the animals not displaying 
paralysis were excluded from the study) and then once a week for 
six consecutive weeks.
2.5.1 | Electrophysiology
Two weeks after injury, animals were anesthetized with 1.5 g/kg of 
urethane via intraperitoneal injection and were secured in a stere‐
otaxic frame (Stoelting Co., Wood Dale, IL). Body temperature was 
kept constant (36.5°C) using a temperature feedback-controlled 
heating pad, and heart rate and partial pressure O2 were constantly 
monitored (Kent Scientific Co., Torrington, CT). An incision was 
made along the midline of the scalp, and the skin was retracted. A 
craniotomy was performed on the right side of the skull exposing 
the hindlimb sensory cortex. A 32-channel, single shank recording 
electrode (A1x32, NeuroNexus, Ann Arbor, MI) was mounted to a 
stereotaxic manipulator and positioned over the hindlimb sensory 
cortex (0.2 mm caudal and 2 mm lateral to bregma), perpendicular 
to the surface of the brain. A cortical screw was inserted into the 
left side of the skull such that it was placed in contact with cerebral 
spinal fluid and was used as the electrode's reference. The electrode 
was advanced into the cortex to a depth of 1.65 mm at a rate of 
approximately 50 µm per minute, while neural signals were ampli‐
fied (192X), band-pass filtered (0.1 Hz-7.5 kHz), and monitored on 
an oscilloscope and through audio speakers. Analogue neural signals 
were acquired and converted to a digital signal at a sampling rate of 
20.0 kS/s and 16-bit quantization (Intan Technologies, Los Angeles, 
CA).
2.5.2 | Peripheral electrical stimulation
Bipolar stimulating electrodes were inserted subcutaneously into 
the ankle of the hindlimb contralateral to the recording site (Figure 
S1A). For each animal, electrical stimulation, consisting of 100 pulses 
at 0.5 Hz with a 1.0 ms pulse duration at 1.0 mA of current, was ap‐
plied as the neural response was recorded.
2.5.3 | Evoked responses
Local field potentials (LFPs) were obtained from each recording site 
on the electrode by applying a low-pass filter (200 Hz, Butterworth 
order 5, Zero lag) to the raw signal. One second windows of neural 
data centered around each stimulation time point were averaged 
across all stimulation trials in a single recording to generate a sensory 
evoked potential (SEP). A representative channel from the supra‐
granular (150 µm depth), granular (500 µm depth), and infragranular 
(800 µm depth) layers of the cortex was selected for further anal‐
ysis. We then evaluated whether there was a cortical response to 
the stimulation. For each layer, the SEP was considered responsive 
whether its peak amplitude exceeded a response threshold equal to 
the mean plus 3 standard deviations of the background activity. For 
each responsive SEP, the amplitude was calculated as the difference 
between the SEP peak amplitude and the response threshold. If the 
SEP peak amplitude did not exceed the response threshold, it was 
considered not responsive, and the value of the SEP amplitude was 
set to zero. The SEP latency was evaluated for responsive SEPs and 
was defined as the time of the SEP peak amplitude relative to the 
stimulation. The proportion of positive responses, and the SEP am‐
plitudes and latencies for positive responses were compared across 
groups separately for the supragranular, granular, and infragranular 
layers of the hindlimb somatosensory cortex.
To ensure that we were accurately placing the recording sites at 
the proper depth, current source density analysis was used to con‐
firm electrode placement. In naïve animals, CSD profiles of responses 
to hindlimb stimulation were obtained. The strongest current sink in 
the naïve animals corresponded to a depth of 500 microns and was 
estimated to be the granular layer (Figure S1B,C).21‐24
2.6 | Spinal cord tissue analysis
Measurement of lesion volume and immunohistochemistry: The ani‐
mals were perfused transcardially with phosphate‐buffered saline 
followed by ice-cold 4% paraformaldehyde (PFA). The tissue was 
postfixed for 4 hours in PFA before transfer to 25% sucrose over‐
night. The cords were embedded and frozen in OCT (Tissue-Tek) 
before sectioning with a cryostat. Thirty micrometre transversal 
sections were stained using rabbit anti-GFAP antibodies (1:1000, 
DAKO) to identify the edge of the lesion. Four sections 300 µm 
apart were used, and the volume of the lesion was estimated using 
the Stereology Module of Slidebook6 software. TUNEL staining was 
performed to identify cell death using the ApopTag staining kit (EMD 
Millipore).
2.7 | Protein expression and RNA analysis
0.5 cm long segments of spinal cord tissue centered on the lesion 
site were collected at various time points after injury following 
PBS perfusion of the animals (different animals from BMS group) 
and flash-frozen on dry ice. For proteins, the tissues were lysed 
in RIPA buffer (10 mmol/L sodium phosphate pH 7.2, 150 mmol/L 
NaCl, 2 mmol/L EDTA, 1% sodium deoxycholate, 1% NP-40, 0.1% 
sodium dodecyl sulfate) supplemented with protease inhibitors 
(Pierce tablets) and phosphatase inhibitors (BioVision). Proteins 
were resolved on SDS-PAGE gels before being transferred onto 
nitrocellulose membranes using the Trans‐Blot® Turbo™ system 
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(Bio-Rad). Antibodies for the Western blot detection included 
rabbit anti‐CNPase (1:5000; Cell signaling), mouse anti‐NF200 
(1:5000; Sigma), rabbit anti‐PI3Kγ (1:500; Santa Cruz), and mouse 
anti‐β-tubulin (1:60 000; Sigma).
RNAs were extracted using TRIzol (Thermo Fisher) following 
the manufacturer's instructions. RT-PCR was performed with the 
Omniscript RT kit (Qiagen) followed by qPCRs performed using the 
Rotor‐Gene SYBR® Green PCR Kit, and the Rotor‐Gene Q real‐time 
PCR cycler (Qiagen). Each gene expression levels were determined 
using a standard curve for that gene, and the data were normal‐
ized to β‐actin expression levels. The primers used are listed in the 
Table S2.
2.8 | Statistical analysis
Comparisons between groups were performed using one‐way analy‐
sis of variance (ANOVA) followed by post hoc Tukey's test. If only 
two groups, a two‐tailed t test was used.
F I G U R E  1   Effect of TNFR2 activation 
on glutamate‐induced neuronal cell death. 
A, Timeline of the experiment. B, Effect 
of pretreatment with EHD2‐sc‐mTNFR2 
on glutamate‐induced neuronal cell death. 
Cells were pretreated for 12 h, 24 h, or 
48 h prior to addition of 300 μmol/L of 
glutamate. C, Effect of treatment with 
EHD2‐sc‐mTNFR2 at time (0h) or 6 h prior 
the addition of glutamate on cell death. D, 
Role of PI3Kγ in the protection provided 
by EHD2‐sc‐mTNFR2 on glutamate‐
induced neuronal cell death. Cells were 
pretreated for 6 h with EHD2-sc-mTNFR2 
alone or in combination with either A66 
(PI3K/p110α inhibitor) or AS 605240 
(PI3K/p110γ inhibitor). E, Role of p38 
MAPK in glutamate-induced cell death. 
Cells were pretreated for 4 h with either 
EHD2‐sc‐mTNFR2 alone or with SB203580 
(p38 inhibitor). All bar graphs represent 
the mean ± SEM of eight separate samples 
for each condition. ****P < 0.0001; 
***P < 0.001; **P < 0.01; *P < 0.05 
(compared to untreated controls). 
ººººP < 0.0001; ºººP < 0.001; ººP < 0.01; 
ºP < 0.05 (compared to glutamate 
controls). +P < 0.05, ++++P < 0.0001 
(compared to glutamate/EHD2‐sc‐
mTNFR2)
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2.8.1 | Behavior
A two-way ANOVA was performed.
2.8.2 | Electrophysiology
The proportion of responses was compared across groups for each 
layer separately using the chi-squared test with the Fisher's exact 
test post hoc. Changes in SEP amplitude and latency were not nor‐
mally distributed. Kruskal‐Wallis test was used to evaluate statistical 
differences in SEP amplitude and latency between groups, separately 
for each layer. Post hoc Mann-Whitney U test assessed differences 
between PBS controls and treated animals if the Kruskal‐Wallis was 
significant. All results were considered statistically significant at 
P < 0.05.
3  | RESULTS
3.1 | Activation of TNFR2 protects neurons against 
glutamate‐induced cell death
Given the body of evidence describing the neuroprotective role 
of TNFR2, we studied how neurons would respond to stimulation 
with a specific agonist for this receptor. A previous study demon‐
strated a protective effect against glutamate excitotoxicity after an‐
tibody‐mediated pre‐activation of TNFR2 through the activation of 
PI3 kinase.25 We reexamined these experiments with the specific 
agonist EHD2‐sc‐mTNFR2 (Figure 1A). A short pretreatment (6 hours) 
with TNFR2 agonist before treatment with glutamate decreased 
noticeably the amount of cells dying compared to cells pretreated 
for a longer time (12, 24 or 48 hours) (Figure 1B, C). Interestingly, 
stimulation of TNFR2 performed simultaneously with exposure to 
glutamate was also able to prevent the neurons from dying as ef‐
fectively as a treatment with the agonist initiated 6 hours earlier 
(Figure 1C). Using inhibitors targeting different classes of PI3K cata‐
lytic subunits, we observed that p110γ was the protein mediating 
the signal provided by TNFR2 activation (Figure 1D), as treatment 
with AS605240 abrogated the protective effect elicited by EHD2-
sc‐mTNFR2. A similar experiment using the p110α inhibitor A66 did 
not block the protective effect triggered by TNFR2 stimulation. We 
then examined the potential involvement of p38 MAPK on the path‐
way activated by EHD2‐sc‐mTNFR2 as this kinase has been impli‐
cated in PI3Kγ signaling26 and observed that its inhibition abolished 
the protection from glutamate excitotoxicity provided by activation 
of TNFR2 (Figure 1E).
3.2 | Effect of EHD2‐sc‐mTNFR2 on recovery 
following spinal cord injury
Since activating TNFR2 with a specific agonist can have effects on 
two cell types (neurons and oligodendrocytes) that would be con‐
sidered positive in order to mitigate the consequences of spinal 
cord trauma, we then analyzed whether infusion of the agonist di‐
rectly into the spinal cord tissue after injury in mice could reduce 
F I G U R E  2   Effect of EHD2‐sc‐mTNFR2 
on locomotion after spinal cord injury. A, 
Effect of TNFR2 agonist on locomotion 
recovery (assessed by BMS scoring 1 d 
after injury and weekly thereafter for 
6 weeks). *P < 0.05. B, Representative 
longitudinal sections of spinal cords 
showing the lesion 2 wk after contusive 
injury. Blue: Hoechst; red: staining for 
GFAP. C, Representative images of the 
TUNEL staining in spinal cords 2 wk 
after injury. D, Quantification of lesion 
size. E, Quantification of TUNEL-positive 
cells detected in the spinal cord 2 weeks 
following injury. Bar graphs represent the 
mean ± SEM of n = 6 PBS and n = 5 EHD2-
sc‐mTNFR2* P < 0.05
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the extent of damage and/or promote repair. EHD2‐sc‐mTNFR2 was 
infused continuously over a month and locomotion assessed weekly 
with the BMS test. We observed that stimulation of TNFR2 in the 
cord tissue improved the locomotion of the animals (Figure 2A). A 
significant improvement was observed at 1 and 2 weeks after in‐
jury, with greater BMS scores measured for the entire testing pe‐
riod. The improved locomotion did not result from extensive sparing 
of cord tissue as the lesion size was similar regardless of treatment 
(Figure 2B, D), even with greater numbers of TUNEL-positive cells 
detected, indicating increased cell death (Figure 2C, E). The levels 
of several proteins that could provide insight about the pathological 
changes taking place in the spinal cord were examined. No changes 
in any protein analyzed were observed before 6 weeks after injury 
when significantly higher levels of neurofilament H (NF200) and 2′, 
3′-cyclic-nucleotide 3′-phosphodiesterase (CNPase) were detected 
(Figure 3A, B). Several proteins studied, especially proteins that 
are part of the myelin sheath such as myelin basic protein (MBP) 
or proteolipid protein (PLP), did not appear to be affected by our 
treatment. We also did not observe any changes in the expression 
of glial fibrillary acidic protein (GFAP) or Iba-1, a marker of activated 
microglia (not shown). Interestingly, although we identified PI3Kγ as 
a mediator of the neuroprotection pathway activated by TNFR2, the 
levels of that protein were significantly lower after treatment with 
the TNFR2 agonist 6 weeks following the contusion compared to 
PBS treatment (Figure 3B).
3.3 | TNFR2 activation does not modulate cytokine 
expression in the acute phase
TNFR2 stimulation has been associated with a decrease in immuno‐
logical response in some models, which led us to consider whether 
the modulation of early inflammatory signaling could be affected by 
the TNFR2 agonist. The levels of some gene transcripts involved in 
inflammatory pathways were analyzed 6h and 1d after contusion in 
F I G U R E  3   Expression levels of 
proteins around the lesion site following 
spinal cord injury. A, Expression of 
CNPase, neurofilament H (NF200), 
and PI3Kγ 2 weeks following injury. 
Bar graphs represent the mean ± SEM 
of n = 3 naïve (N), n = 4 PBS, and n = 6 
R2A. ***P < 0.001; **P < 0.01; *P < 0.05. 
B, CNPase, NF200, and PI3Kγ protein 
expression, 6 weeks following injury. Last 
sample in the NF200 blot was an outlier 
as determined by the Grubb's method 
and was excluded from the bar graph. 
Bar graphs represent the mean ± SEM 
of n = 3 naïve, n = 6 PBS, and n = 5 R2A 
***P < 0.001; **P < 0.01; *P < 0.05. PBS: 
spinal cord injured controls infused with 
PBS; R2A: spinal cord injured animals 
infused with EHD2‐sc‐mTNFR2
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the spinal cord, but we did not observe any significant changes trig‐
gered by TNFR2 agonist in the levels of TNF, IL-1β, IL-33, CCL2, and 
CXCL10 compared to PBS (Figure 4 ).
3.4 | Enhanced cortical response activation after 
spinal cord injury following TNFR2
Finally, a mounting body of evidence points to axon sprouting and 
cortical reorganization that can contribute to the recovery follow‐
ing spinal cord injury, even in the case of a complete transection.27 
To determine whether the effect of the TNFR2 agonist could affect 
the cortical response to sensory stimuli, the response to hindlimb 
stimulation was compared across groups. As expected, the in‐
jury resulted in a sharp decrease in the amplitude of the SEP for 
all three layers (Figure 5B) (supragranular: H(2) = 18.636, P < 0.05; 
granular: H(2) = 14.568, P < 0.05; and infragranular: H(2) = 16.311, 
P < 0.01). However, treatment with EDH2‐sc‐mTNFR2 resulted in a 
significantly greater amplitude of the SEP for the infragranular layer 
compared to the animals infused with PBS only (Figure 5A, B) (U 
(1) = 30, Z = 2.015, P < 0.05, Cohen's R = 0.43). Moreover, the SEP 
latency was significantly longer in the infragranular layer follow‐
ing infusion with the TNFR2 agonist (Figure 5C) (U (1) = 0, z = −2, 
P < 0.05, Cohen's R = −0.7). Given the layer specificity of the effect 
on amplitude and latency, it is worth noting that, in the infragranular 
layer, there was a trend for more positive responders in the animals 
infused with the TNFR2 agonist compared to the ones infused with 
PBS (Fisher's test, P = 0.063). Together, these data suggest that, in 
animals treated with EHD2‐sc‐mTNFR2, sprouting at the level of the 
lesion may increase the probability of an evoked response and those 
responses will have a larger amplitude and longer latency than in 
animals where TNFR2 was not stimulated.
4  | DISCUSSION
We report observing several potentially beneficial effects pro‐
moted by the specific activation of TNFR2 following spinal cord 
injury that could contribute to a positive effect on the recovery 
process. The infusion of the agonist EHD2‐sc‐mTNFR2 over a 
month after contusive thoracic spinal cord injury allowed the ani‐
mals to exhibit better locomotion as assessed with the BMS test. 
Early activation of TNFR2 did not reduce inflammation, as could 
have been suspected from recent work demonstrating that the 
activation of that receptor in microglia curbs the inflammatory re‐
sponse in experimental autoimmune encephalomyelitis.28 TNFR2 
activation may also have a direct protective effect on neurons in 
the cord as it is able to preserve them in vitro from an exposure to 
excessive glutamate concentrations, which are known to increase 
following spinal cord injury and cause excitotoxic cell death.29,30 
We present evidence here that the activation of TNFR2 does not 
F I G U R E  4   Acute response of genes 
linked to the inflammatory response 
after spinal cord injury. The RNA levels 
were measured 6 h and 1 d after injury 
by quantitative real‐time PCR. Data for 
each gene were normalized to β‐actin and 
expressed as a percentage of the naïve 
uninjured control. Bar graphs represent 
the mean ± SEM of n = 3/group/time 
point *P < 0.05, **P < 0.01, ***P < 0.001, 
****P < 0.0001
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need to precede the glutamate insult as previously thought,25 but 
rather that it can occur simultaneously and that it is mediated by 
PI3Kγ. We observed a noticeably stronger protective effect with 
shorter times between TNFR2 stimulation and glutamate expo‐
sure (0 or 6 hours, compared to 12 hours and up), suggesting that 
the signaling may be downregulated to levels inadequate to pro‐
vide complete protection from glutamate excitotoxicity if TNFR2 
gets activated too early. Surprisingly, while PI3Kγ was increased at 
2 weeks after injury, there was no difference between EHD2‐sc‐
mTNFR2 and PBS treated groups. Furthermore, the levels of PI3Kγ 
were significantly lower at 6 weeks in the group treated with the 
TNFR2 agonist compared to PBS. However, any neuroprotective 
effect mediated by PI3Kγ would most likely occur early after in‐
jury, within hours or a few days at most. Besides its protective 
effect from glutamate‐induced excitotoxicity, PI3Kγ contributes 
to neuroinflammation,31 and a decreased expression because of 
activation of TNFR2 could prevent inflammation to be sustained at 
levels that could prove harmful over long periods of time. Despite 
the positive effects observed in vitro on neurons in our study and 
OPCs9,10 following TNFR2 stimulation, we could have expected 
some tissue sparing to be the result of EHD2‐sc‐mTNFR2 infu‐
sion, yet we did not observe substantive changes in the size of 
the lesion. One potential effect of TNFR2 stimulation on neurons 
that could result in improved behavior in the absence of increased 
tissue sparing may be enhanced neural circuit reorganization as 
suggested by our electrophysiological recordings. Infusion with 
EHD2‐sc‐mTNFR2 increased the probability of an evoked response 
having a larger amplitude and a longer latency following hindlimb 
stimulation, which may be explained by enhanced connectivity 
due to sprouting and an increased number of synapses for the sig‐
nal to cross. Cortical reorganization following spinal cord injury 
can be associated with increased pain.32 However, TNFR2 activa‐
tion can stimulate the expansion of the population of T‐regulatory 
cells,33,34 which can alleviate pain in experimental autoimmune 
encephalomyelitis.35 T‐regulatory cells are also neuroprotective 
and can favor myelination in the CNS.36,37 Our study yielded one 
counterintuitive result when we observed an increased number of 
cells dying as a result of TNFR2 activation in the cord. Such an 
increase could be expected to correlate with greater tissue dam‐
age and poorer behavioral outcome, yet we observed the oppo‐
site on both counts. We were not able to accurately characterize 
the phenotype of the TUNEL-positive cells as specific proteins are 
lost during apoptosis. Our in vitro data would tend to suggest that 
the cells dying in greater numbers may not include neurons, and 
possibly oligodendrocytes. The survival of immune cells, such as T 
cells and macrophages, has been shown to be sensitive to TNFR2 
stimulation.38,39 These cells are among many that infiltrate the 
cord following injury and that can both participate to the healing 
or the exacerbation of the damage caused by injury,40 and their 
elimination, after performing beneficial duties such as phagocy‐
tosing debris in the case of macrophages, could prove beneficial.
Our data describe a positive effect triggered by stimulation of 
the TNFR2 receptor in the spinal cord following a contusive injury 
that may have several origins. The most promising and possibly most 
important one is the effect on neurons, where these cells could be 
spared from secondary injury processes in greater numbers and be 
F I G U R E  5   Effect of TNFR2 
activation in the injured spinal cord 
on somatosensory evoked responses 
(SEP) in the hindlimb cortex. A, 
Representative trace of SEP recorded 
from the infragranular layer following 
hindlimb stimulation. B, Quantification 
of the amplitude of SEP recorded from 
three cortical layers. Injured animals 
have smaller amplitudes compared to 
naïve ones, but stimulation of TNFR2 
increases significantly the amplitude of 
SEP recorded in the infragranular layer. 
*P < 0.05. C, Quantification of the latency 
of SEP recorded from three cortical 
layers. The animals treated with EHD2‐
sc‐mTNFR2 show a significantly greater 
latency for the SEP recorded in the 
infragranular layer. *P < 0.05
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stimulated to sprout and establish more connections to bypass the 
site of injury.
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